AMR Clinical's Ohio Buy Signals Deeper Consolidation in Research Sector

KNOXVILLE, TN & RESEARCH TRIANGLE PARK, NC – June 29, 2026 – In a move that underscores a significant trend toward consolidation in the clinical research industry, AMR Clinical announced today its acquisition of ClinOhio Research Services. The deal expands AMR's national footprint into the key Columbus, Ohio market and deepens its expertise in high-demand therapeutic areas, signaling a calculated step in a market racing to streamline the path from drug development to patient delivery.

While the financial terms were not disclosed, the strategic value is clear. This acquisition is more than a simple line-item expansion; it's a window into the evolving landscape of clinical trials, where scale, specialization, and operational efficiency are becoming the primary currencies for success. For pharmaceutical sponsors, investors, and patients, moves like this are a critical indicator of how the industry is re-engineering itself to accelerate medical innovation.

A Calculated Move in a Booming Market

The acquisition of ClinOhio is the latest chapter in AMR Clinical's deliberate growth narrative. Founded in 1994 and fully integrated as a site network in 2017, the company has been on an aggressive expansion trajectory, particularly since partnering with private equity firm Curewell Capital in 2021. This partnership was explicitly designed to fuel growth through strategic acquisitions, a strategy that has seen AMR more than double its size to over 30 sites across the United States in the last five years.

This strategy is playing out in a market ripe for consolidation. The clinical trial investigative site network market, valued at approximately $9.2 billion in 2025, is projected to surge to $18.7 billion by 2036. This explosive growth is driven by a confluence of factors: rising investment in drug development, the increasing prevalence of chronic diseases, and a global push to bring new therapies to market faster.

In this environment, standalone research sites, despite their local expertise, face increasing pressure. Larger, integrated networks like AMR Clinical offer pharmaceutical sponsors a streamlined, single-point-of-contact solution. They promise standardized operating procedures, centralized contracting, and access to a vast, diverse patient database—AMR's boasts over one million participants—which can significantly reduce trial startup times and improve data consistency.

The ClinOhio acquisition fits perfectly within this framework. It follows a similar pattern to AMR's December 2023 purchase of Affinity Health, which brought sites in Chicago and Nashville into the fold. By acquiring ClinOhio, AMR not only gains a foothold in a new, strategic geographic market but also absorbs a team with a proven track record.

"ClinOhio brings experienced investigators, strong patient relationships, and a clear commitment to high-quality research," said Kari L. Delahunty, Chief Executive Officer of AMR Clinical, in the official announcement. "This acquisition advances our therapeutic expansion while maintaining the standard of excellence that defines AMR." Delahunty, who stepped into the CEO role in late 2025, is known for her operational expertise and is clearly executing on a vision of scalable, high-quality growth.

Integrating Expertise and Expanding Access

For AMR, the deal is a targeted enhancement of its therapeutic capabilities. ClinOhio has built a strong reputation since its 2017 founding for its rigorous, physician-led research in Dermatology, Women's Health, and Gastroenterology. These are areas with significant ongoing drug development pipelines, making specialized expertise a valuable asset. By integrating ClinOhio's team and knowledge base, AMR strengthens its value proposition to sponsors focused on these specific fields.

From ClinOhio's perspective, the acquisition provides a pathway to greater impact. While successful as an independent entity, joining a national network offers resources and scale that are difficult to build from the ground up.

"Joining AMR marks an exciting new chapter for our team and the patients we serve," noted Jim Sanders, Founder and Owner of ClinOhio Research Services. He emphasized that AMR's infrastructure and national reach will allow his team to "take on more complex protocols, support a broader range of sponsors, and expand access to clinical trials in our community."

This sentiment highlights a crucial synergy. AMR gains specialized, on-the-ground expertise and community trust, while ClinOhio gains access to AMR's centralized support functions, established sponsor relationships, and robust data capabilities. The integration plan aims to leverage this synergy to drive growth at the Columbus site, enhance execution consistency, and ultimately, enable more complex and ambitious clinical trials. This isn't just about getting bigger; it's about getting better and more capable.

The Commercialization Engine: Fueling Sponsors and Empowering Patients

Ultimately, the success of this acquisition will be measured by its impact on the commercialization pipeline. For the biopharmaceutical and medical device companies that sponsor clinical trials, integrated site networks are becoming indispensable partners. The consolidation trend, exemplified by the AMR-ClinOhio deal, directly addresses major pain points for these sponsors.

By offering a single, unified platform across more than 30 sites, AMR can accelerate study startup, a notorious bottleneck in drug development. Sponsors can negotiate one master contract instead of dozens, and they can rely on consistent data collection and reporting standards across the network. The addition of ClinOhio enhances this by providing a ready-made pool of engaged patients and experienced investigators in a new demographic region, broadening the potential for faster trial enrollment. The specialized expertise in Dermatology, Women's Health, and Gastroenterology means sponsors in these fields have a more reliable, expert partner to execute their studies.

The benefits extend directly to patients, particularly in the Columbus area. The integration with AMR's national network means the ClinOhio site will now be able to attract a wider and more diverse range of clinical trials. This provides local residents with greater access to potentially life-changing investigational therapies and advanced medical care they might not otherwise receive.

This dual benefit—streamlining the path to profit for sponsors while expanding access and care for patients—is the core engine of the modern clinical research site network. As AMR Clinical continues to methodically build its integrated platform, it reinforces a fundamental shift in how medical innovations are tested and brought to market, turning strategic acquisitions into a direct catalyst for scientific progress.